Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has increased by 3.25%
3 days ago•Economic Times
4 days ago•Bloomberg Quint
4 days ago•Business Standard
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download
Final • Div/Share: ₹ 0.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant